Last reviewed 2026-04-20 · How we verify

MK0777

Merck Sharp & Dohme LLC · Phase 2 active Small molecule Quality 0/100

At a glance

Generic name	MK0777
Sponsor	Merck Sharp & Dohme LLC
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of MK0777 in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-020) (PHASE2)
GEM 1.5 mg b.i.d. to 4.5 mg b.i.d. Versus Lorazepam in GAD (0777-026) (PHASE2)
A Study of MK0777 Gel Extrusion Module (GEM) in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-019) (PHASE2)
Treatment of Patients With Anxiety Disorder (0777-022) (PHASE2)
Treatment Study for Cognitive Deficits in Schizophrenia (PHASE2)
Gamma-Amino Butyric Acid (GABA)-A Alpha2/3 Study (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results